Aspect Biosystems - About the company
Aspect Biosystems is a series B company based in Vancouver (Canada), founded in 2013 by Tamer Mohamed and Sam Wadsworth. It operates as a Developer of bioprinting technology and tissue therapeutics for regenerative medicine. Aspect Biosystems has raised $139M in funding from investors like Pangaea Ventures, Radical Ventures and Dimension. The company has 95 active competitors, including 21 funded and 12 that have exited. Its top competitors include companies like Xlife sciences, CurifyLabs and ROKIT Healthcare.
Company Details
Developer of bioprinting technology and tissue therapeutics for regenerative medicine. The company’s platform integrates bioprinting, computational design, therapeutic cells, and biomaterials. It develops implantable tissues to replace, repair, or supplement biological functions. The focus is on creating solutions for metabolic and endocrine diseases. The company also collaborates with other organizations.
- Website
- aspectbiosystems.com
- Social
- Registered Address
- 1600 - 925 West Georgia Street, Vancouver
Key Metrics
Founded Year
2013
Location
Vancouver, Canada
Stage
Series B
Total Funding
$139M in 5 rounds
Latest Funding Round
Investors
Ranked
1st among 95 active competitors
Employee Count
148 as on Sep 30, 2026
Similar Companies
Legal entities associated with Aspect Biosystems
Aspect Biosystems is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Aspect Biosystems Ltd. CIN: 870153-9 , Canada, Active | Nov 19, 2013 | - | - | - |
Aspect Biosystems Ltd. CIN: 11990721 , Canada, Active | Apr 03, 2020 | - | - | - |
Sign up to download Aspect Biosystems' company profile
Aspect Biosystems's funding and investors
Aspect Biosystems has raised a total funding of $139M over 5 rounds. Its first funding round was on Sep 18, 2017. Its latest funding round was a Series B round on Jan 08, 2025 for $*****. 8 investors participated in its latest round. Aspect Biosystems has 23 institutional investors.
Here is the list of recent funding rounds of Aspect Biosystems:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 08, 2025 | 7819617 | Series B | 4782139 | 4417569 | 2609916 | 3980104 |
Jan 09, 2020 | 7730133 | Series A | 1805517 | 1790755 | 5999293 | |
Nov 15, 2018 | 7147670 | Series A | 4399383 | 4504240 | 7531813 |
Access funding benchmarks and valuations. Sign up today!View details of Aspect Biosystems's funding rounds and investors
Aspect Biosystems' founders and board of directors
Founder? Claim ProfileThe founders of Aspect Biosystems are Tamer Mohamed and Sam Wadsworth. Tamer Mohamed is the CEO of Aspect Biosystems.
Here are the details of Aspect Biosystems' key team members:
- Tamer Mohamed: Co-Founder & CEO of Aspect Biosystems. Contact Info: 1 email address
- Sam Wadsworth: Co-Founder & CSO of Aspect Biosystems. Contact Info: 1 email address
View details of Aspect Biosystems's Founder profiles and Board Members
Aspect Biosystems' employee count trend
Aspect Biosystems has 148 employees as of Sep 26. Here is Aspect Biosystems's employee count trend over the years:
Uncover Aspect Biosystems' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Aspect Biosystems's Competitors and alternates
Top competitors of Aspect Biosystems include Xlife sciences, CurifyLabs and ROKIT Healthcare. Here is the list of Top 10 competitors of Aspect Biosystems, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Aspect Biosystems 2013, Vancouver (Canada), Series B | Developer of bioprinting technology and tissue therapeutics for regenerative medicine | $139M | 70/100 | |
2nd |  Xlife sciences 2013, Zurich (Switzerland), Public | Developer of drugs for multiple diseases | $62.8M | - | 58/100 |
3rd |  CurifyLabs 2021, Helsinki (Finland), Series A | Provider of digital 3D printing solutions for personalized medicine | $33.8M | 57/100 | |
4th | ROKIT Healthcare 2012, Seoul (South Korea), Public | Provider of 4D bio-printer solutions for tissue regenerative | $30M | 54/100 | |
5th | Allevi 2014, Philadelphia (United States), Acquired | 3D bioprinting solutions: bioprinters, bioinks, and software for tissue engineering | $2.33M | 47/100 | |
6th | FabRx 2014, London (United Kingdom), Unfunded | 3D printed drugs | - | - | 47/100 |
7th | _1568284234590.png?devicePixelRatio=2&height=30&width=30){kind=logo} CTIBiotech 2009, Lyon (France), Funding Raised | Develops 3D human tissue models | - | 46/100 | |
8th | Developer of 3D tissue engineering technology | $16.6M | 45/100 | ||
9th |  BICO 2016, Boston (United States), Public | Provider of technologies, products, and services for life sciences research purposes | - | 45/100 | |
10th | CELLINK 2016, Boston (United States), Public | Developer of 3D bioprinters and bioinks for research purposes | - | 43/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Aspect Biosystems's competitors? Click here to see the top ones
Aspect Biosystems's Investments and acquisitions
Aspect Biosystems has made no investments or acquisitions yet.
Reports related to Aspect Biosystems
Here is the latest report on Aspect Biosystems's sector:
News related to Aspect Biosystems
Filter this listMedia has covered Aspect Biosystems for a total of 4 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
Aspect Biosystems expanding cellular medicine work with $79 million government fundingVoxelMatters•Jul 24, 2026•Aspect Biosystems
•
Canada Invests $127M in Aspect Biosystems & Providence Health Care for Biomanufacturing.CNW•Apr 03, 2026•Aspect Biosystems
•
Aspect Biosystems and Novo Nordisk Enter New Phase of Partnership for Diabetes MedicinesGlobeNewswire•Jan 20, 2026•New Nordic, Aspect Biosystems
•
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025Financial Post•Jul 15, 2025•Aspect Biosystems
•
British Columbia's Startup Fund Considers Growth, Private CapitalFinancial Post•Jul 14, 2025•InBC, Aspect Biosystems
•
Aspect Biosystems raises US$115m Series BAngel News•Jan 17, 2025•Aspect Biosystems, New Nordic, Radical Ventures, InBC and 10 others
•
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue TherapeuticsBusiness Wire•Jan 08, 2025•Aspect Biosystems, InBC, Pallasite Ventures, Pangaea Ventures and 6 others
•
Aspect Biosystems Secures $72.75M for Bioprinted Tissue TherapeuticsTechcouver•Jul 10, 2024•Aspect Biosystems, Government of Canada, Fast Company, Government of British Columbia
•
Aspect Biosystems Named to Fast Company’s 2023 List of the Next Big Things in TechBusiness Wire•Nov 28, 2023•Aspect Biosystems
•
Aspect Biosystems, Novo Nordisk Partner to Develop Bioprinted Tissue TherapeuticsPharmtech•Apr 25, 2023•Aspect Biosystems, New Nordic
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Aspect Biosystems
Explore our recently published companies
- Frukt AS - Norway based, Unfunded company
- Ojha Sir Gyanshala - Unfunded company
- Ozeku - Unfunded company
- Mainmeditech - China based, 2020 founded, Unfunded company
- MOBYLIZ - France based, 2020 founded, Unfunded company
- Dave Carmack - Unfunded company
